Michael K Keng
Overview
Explore the profile of Michael K Keng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mort M, Sen J, Morris A, DeGregory K, McLoughlin E, Mort J, et al.
J Oncol Pharm Pract
. 2019 Sep;
26(3):680-687.
PMID: 31500517
Background: Acute myeloid leukemia patients receive anthracycline-containing induction chemotherapy. Anthracyclines cause cardiotoxicity; however, there is a paucity of data reflecting the risk of cardiotoxicity in the acute myeloid leukemia population,...
12.
Keng M, Thallner E, Elson P, Ajon C, Sekeres J, Wenzell C, et al.
J Oncol Pract
. 2015 Jul;
11(6):450-5.
PMID: 26220930
Purpose: Febrile neutropenia (FN) is an oncologic emergency, and prolonged time to antibiotic administration (TTA) is associated with increased hospital length of stay (LOS) and worse outcomes. We hypothesized that...
13.
Keng M, Wenzell C, Sekeres M
Clin Adv Hematol Oncol
. 2014 Feb;
11(10):646-55.
PMID: 24518374
In the United States, drugs and medical devices are regulated by the US Food and Drug Administration (FDA). A drug must undergo rigorous testing prior to marketing to and medical...
14.
Keng M, Sekeres M
Curr Hematol Malig Rep
. 2013 Aug;
8(4):370-8.
PMID: 23990311
Febrile neutropenia (FN) can occur at any time during the course of a malignancy, especially hematologic malignancies, from diagnosis to end-stage disease. The majority of FN episodes are typically confined...
15.
16.
Wetzler M, Earp J, Brady M, Keng M, Jusko W
Clin Cancer Res
. 2007 Apr;
13(7):2261-70.
PMID: 17404111
Purpose: Constitutive signal transducer and activator of transcription 3 (STAT3) activity, observed in approximately 50% of acute myelogenous leukemia cases and associated with adverse treatment outcome, is down-regulated by arsenic...